Valiant Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on May 20, 2025.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valiant Laboratories' board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Standalone FY25 revenue from operations stood at ₹13,336.18 lakhs (down from ₹18,205.24 lakhs in FY24), with net profit of ₹215.02 lakhs vs ₹34.03 lakhs in FY24. Consolidated FY25 swung to a net loss of ₹220.12 lakhs from a ₹31.96 lakh profit last year, dragged by subsidiary performance. The statutory auditor (Raman S. Shah & Co.) issued an unmodified opinion. The board also re-appointed Ketki D Visariya & Co. as Cost Auditor and Rajesh Chheda & Co. as Internal Auditor for FY 2025-26.
Mixed signals for shareholders — standalone profitability improved sharply YoY but consolidated entity slipped into a loss, mainly due to the subsidiary (Valiant Advanced Sciences). The Company Secretary's resignation for an 'alternate career opportunity' is routine but worth noting; the company has time until June 15 to find a replacement.